Late-Breaking Abstract Parallel sessions feature oral presentations from the authors of cutting-edge, highly-rated abstracts submitted for presentation at The Liver Meeting.

Please join us for an engaging and highly anticipated educational panel presentation focusing on a treatment option for patients with MASH, including the clinical data and patient cases.<br />
<br />
Industry Supporter: Madrigal

In this session, presenters will explore emerging research on alcohol-associated liver disease (ALD), with a focus on severe alcohol-associated hepatitis (SAH). The session will highlight long-term outcomes following hospitalization and early liver transplantation for SAH, as well as introduce a novel therapeutic approach to its treatment. Additionally, it will examine a newly identified genetic risk modifier for ALD and investigate the potential influence of cannabis use on disease risk. Together, these abstracts aim to deepen understanding of disease mechanisms, treatment strategies, and risk factors in ALD.

Join our experts as they discuss practical aspects of integrating liver-directed therapy for the treatment of MASH. Listen as they discuss real-world successes and challenges with using THR-B agonists and GLP-1RAs. Catch up on the latest data on noninvasive testing and other treatments in late-stage development.&nbsp;<br />
<br />
Supported by: Madrigal Pharmaceuticals<br />
<br />
Organized by: AKH Inc., Advancing Knowledge in Healthcare and&nbsp;Catalyst Medical Education, LLC.<br />
<br />
Link:&nbsp;<a href="https://www.eventbrite.com/e/a-new-era-in-mash-how-disease-specific-the… />
<br />
Important Note: Continuing education credits for Satellite Symposia are offered by the sponsoring organizations. These sessions are not accredited by AASLD.

Please join us for an engaging and highly anticipated educational panel presentation focusing on a treatment option for patients with MASH, including the clinical data and patient cases.<br />
<br />
Industry Supporter: Madrigal

Abstract Parallel sessions feature oral presentations from the authors of highly-rated abstracts submitted for presentation at The Liver Meeting.

This is a Healthy Liver, Healthy Lives (HLHL) symposium bringing the global community together to elevate liver disease as a global health priority.

The American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) have jointly led a multi-stakeholder Consensus Process focused on the use of surrogate endpoints and real-world evidence in the design of clinical trials for Primary Biliary Cholangitis (PBC). This collaborative initiative culminated in a Consensus Conference held during the 2025 EASL Congress in Amsterdam, bringing together global experts, regulatory authorities, patient representatives, and industry stakeholders. This session will feature presentations of the final recommendations from this consensus process.

Researchers in this abstract parallel session will share the results of recent clinical trials in MASH.